Takeda Pharmaceutical Co Ltd (NYSE:TAK) has received an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation.
Analysts have set a twelve-month consensus price target of $24.25 for the company, according to Zacks. Zacks has also assigned Takeda Pharmaceutical an industry rank of 87 out of 256 based on the ratings given to related companies.
Several research analysts have recently commented on the company. Zacks Investment Research downgraded H&E Equipment Services from a “hold” rating to a “sell” rating in a research note on Wednesday. ValuEngine upgraded Vermillion from a “hold” rating to a “buy” rating in a research note on Wednesday, May 15th.
Shares of NYSE TAK traded down $0.02 during midday trading on Monday, hitting $17.38. 1,085,036 shares of the company’s stock were exchanged, compared to its average volume of 1,306,800. The company has a quick ratio of 0.82, a current ratio of 1.22 and a debt-to-equity ratio of 0.92. Takeda Pharmaceutical has a 12 month low of $15.50 and a 12 month high of $21.95. The business has a 50 day moving average of $17.46. The company has a market capitalization of $27.19 billion, a price-to-earnings ratio of 34.08 and a beta of 0.69.
Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Tuesday, May 14th. The company reported $0.13 EPS for the quarter. Takeda Pharmaceutical had a return on equity of 12.18% and a net margin of 10.60%. The company had revenue of $3.51 billion during the quarter. As a group, equities analysts forecast that Takeda Pharmaceutical will post 0.44 EPS for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in the stock. Shelton Capital Management acquired a new stake in Takeda Pharmaceutical during the 1st quarter worth approximately $46,000. Hudock Capital Group LLC acquired a new stake in Takeda Pharmaceutical during the 1st quarter worth approximately $26,000. Global Retirement Partners LLC lifted its holdings in Takeda Pharmaceutical by 63.3% during the 1st quarter. Global Retirement Partners LLC now owns 3,421 shares of the company’s stock worth $70,000 after purchasing an additional 1,326 shares during the last quarter. Shine Investment Advisory Services Inc. acquired a new stake in Takeda Pharmaceutical during the 1st quarter worth approximately $28,000. Finally, Contravisory Investment Management Inc. acquired a new stake in Takeda Pharmaceutical during the 1st quarter worth approximately $28,000. 11.44% of the stock is owned by institutional investors and hedge funds.
Takeda Pharmaceutical Company Profile
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.
Recommended Story: How to Invest in Growth Stocks
Get a free copy of the Zacks research report on Takeda Pharmaceutical (TAK)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.